Injectable Medications for Weight Management

Primary Recommendations

The American Gastroenterological Association suggests using semaglutide 2.4 mg weekly or tirzepatide 15 mg weekly for weight management, with tirzepatide being the superior alternative if available and tolerated, demonstrating superior weight loss outcomes (20.9% vs. 14.9% mean weight loss at 72 weeks) and greater cardiometabolic benefits 1, 2, 3
Tirzepatide's dual GIP/GLP-1 receptor agonism provides enhanced metabolic benefits through delayed gastric emptying, suppressed appetite, and improved insulin secretion compared to semaglutide's single-receptor action, with a meta-analysis demonstrating tirzepatide 15 mg weekly was associated with 5.1% greater weight loss compared to semaglutide 2.4 mg weekly (95% CI, 0.6%-9.8%) 2

The American College of Cardiology and other guideline societies indicate that these medications are indicated for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia) 1, 2
Blood pressure, signs of pancreatitis or gallbladder disease, nutritional status, and thyroid function should be monitored in patients taking these medications 1, 3

The FDA-approved starting dose of tirzepatide is 5 mg weekly, with titration to 10 mg weekly, then 15 mg weekly based on tolerance and response 2, 3
Semaglutide has a titration schedule starting at 0.25 mg weekly for 4 weeks, increasing to 0.5 mg weekly for 4 weeks, then to 1.0 mg weekly for 4 weeks, 1.7 mg weekly for 4 weeks, and finally to a maintenance dose of 2.4 mg weekly after 16 weeks 3

In patients with type 2 diabetes, these medications offer dual benefits of weight loss and improved glycemic control, though weight loss appears lower in individuals with diabetes (4-6.2%) compared to those without diabetes (6.1-17.4%) 1, 3
Exercise caution when combining these medications with insulin or insulin secretagogues due to potential hypoglycemia risk 3

The average wholesale price is approximately $1,600 for a 30-day supply of semaglutide and $1,272 for tirzepatide, with substantial variability in insurance coverage and patient out-of-pocket costs 1, 3